Profitability
Weight: 25%
D
35
- 5yr Avg ROIC -1.5%
- Operating Margin Trend +35.83 pp/yr
BCRX
BioCryst Pharmaceuticals, Inc.
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
6
- 5yr Avg ROE 0.0%
- 5yr Share-Count CAGR 5.1%
Growth Quality
Weight: 25%
B
72
- 5yr Revenue CAGR 53.6%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 5/5
Cash Generation
Weight: 20%
D+
43
- 5yr FCF Margin -31.2%
- 5yr FCF/NI Conversion 1.24x
Balance Sheet
Weight: 10%
C+
58
- Net Debt / EBITDA 0.58x
- Interest Coverage (EBIT/Int) 4.39x
- Altman Z-Score -6.01
Stability
Weight: 5%
A-
80
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 3
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 4 gurus held; 2 added; 1 trimmed; 1 full exit.
- Holders
- 3 -1
- Avg Δ position
- +46.4%
- New buys
- 0
- Full exits
- 1